Market Overview

UPDATE: Deutsche Bank Raises WuXi PharmaTech's PT

Related WX
WuXi PharmaTech, PRA Health Sciences Restructure Relationship in China for Delivery of Clinical Trial Management Services
The State Of Chinese Company Take-Private Offers: A Look At WuXi PharmaTech

According to a research report published this morning, Deutsche Bank has increased WuXi PharmaTech's (NYSE: WX) PT from $16 to $17.

In the report, Deutsche Bank said, "WX reported another strong quarter, beating street consensus and guidance on top line and EPS. While management reaffirmed guidance for the full year, we think guidance revision is likely in 3Q12 due to 65% and 109% yoy growth in backlogs for service and manufacturing, respectively. We do not foresee operating leverage in the near term due to RMB appreciation and labour cost inflation."

Deutsche Bank maintains its Buy rating on WuXi PharmaTech, which closed Friday at $14.68.

Latest Ratings for WX

Oct 2015Morgan StanleyDowngradesOverweightEqual-Weight
Mar 2015Goldman SachsDowngradesBuyNeutral
Nov 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (WX)

View Comments and Join the Discussion!